In clinical sepsis, it is established that patients reveal enhanced systemic concentrations of complement activation products such as C3a and C5a with inconclusive reports concerning their reliability to predict development of pulmonary dysfunction, clinically manifested as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) [120, 171–173]. The gene discussed is C5; the disease is acute respiratory distress syndrome.